64th ASH Annual Meeting and Exposition: Driving Real-World Evidence for Hematologic Malignancy Research

Special-Interest Sessions

Research, Clinical Practice (Health Services and Quality), Clinical Research, health outcomes research, health disparities research, patient-reported outcomes, Diseases, real-world evidence, Therapies, registries, Lymphoid Malignancies, Myeloid Malignancies

217-219 (Ernest N. Morial Convention Center)

Chair:

William A. Wood, MD, MPH, University of North Carolina at Chapel Hill

Disclosures:

Wood: Pfizer: Research Funding; Genentech: Research Funding; Teladoc: Consultancy; Koneksa Health: Current equity holder in private company, Membership on an entity's Board of Directors or advisory committees; Quantum Health: Consultancy.

Session Introduction

William A. Wood, MD, MPH

Division of Hematology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC

Impact of Real-World Evidence on Research and Clinical Care: Priorities from ASH RC Data Hub

Adam S. Sperling, MD, PhD

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

Impact of Real-World Evidence on Research and Clinical Care: Priorities from EU HARMONY Alliance (1)

Jesús María Hernández-Rivas, MD, PhD

Hospital Salamanca, Salamanca, Salamanca, ESP

Driving RWE for Hematologic Malignancy Research – A Joint ASH RC and EU HARMONY Session (2)

Lars Bullinger, MD

Department of Hematology, Oncology and Tumorimmunology, Charité University Medicine Berlin, Berlin, Germany

Pandemic Preparedness: Highlighting the Role of Real-World Data Hub Programs

William A. Wood, MD, MPH

Division of Hematology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC

Moderated Q&A (10 min)

Samuel Rubinstein, MD

Division of Hematology, University of North Carolina-Chapel Hill, Chapel Hill, NC

HARMONY Alliance: Moving Toward Multicenter Real-World Data Capture in the Hematologic Malignancies in Europe

Konstanze Döhner, MD

Division of Hematology and Oncology, University Hospital Ulm, Ulm, Germany

HARMONY Alliance: Moving Toward Multicenter Real-World Data Capture in the Hematologic Malignancies in Europe - A Patient's Perspective.

Jan Geissler

Leukemia Patient Advocates Foundation, Bern, Switzerland

Building Real-World Research and Collaborative Practice Networks for Malignant Hematology

Donna S. Neuberg, ScD

Department of Data Science, Dana-Farber Cancer Institute, Boston, MA

Building Real-World Research and Collaborative Practice Networks for Malignant Hematology

Brian Huntly, MB ChB, FRCPath, FMedSci, PhD

Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom

A Regulators View: The Impact of Reliable and Relevant Real-World Data on Measuring Safety and Efficacy

Bindu Kanapuru, MD

Office of Oncologic Diseases, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Vienna, VA

A Call to Action and Collaboration

Lars Bullinger, MD

Department of Hematology, Oncology and Tumorimmunology, Charité University Medicine Berlin, Berlin, Germany

Moderated Q&A

See more of: Special-Interest Sessions

<< Previous Session | Next Session >>

Driving Real-World Evidence for Hematologic Malignancy Research – A Joint ASH RC and EU HARMONY Session